Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Ménière's disease

Hearing function after intratympanic application of gadolinium‐based contrast agent: A long‐term evaluation

“…Our results show no long‐term ototoxicity after the intratympanic use of GBCA for MRI. These results confirm the observations of previous studies analyzing hearing thresholds after GBCA, which showed no short‐term side effects or ototoxicity …”

“…Experimental studies with animal models have shown that eightfold diluted GBCA did not have any apparent effects on the stria vascularis of guinea pigs . A previous clinical study with 21 Ménière's disease patients has shown that the intratympanic use of GBCA had no adverse effects on audiological function 1 day after application . Another follow‐up study evaluated the hearing function not only directly after application but also 1 week later.…”

“…8 A previous clinical study with 21 M enière's disease patients has shown that the intratympanic use of GBCA had no adverse effects on audiological function 1 day after application. 9 Another follow-up study evaluated the hearing function not only directly after application but also 1 week later. The results of this study with 65 patients having possible M enière's disease showed no hearing deterioration.…”

Audiologic evaluation of Menière's disease patients one day and one week after intratympanic application of gadolinium contrast agent: Our experience in sixty‐five patients

“…There was, however, no further information about the exact timing of the hearing tests. Another study observed 21 patients and found no short‐term effects on audiologic function 1 day after the injection.…”

“…observed different routes of application of gadolinium‐based contrast agent in humans and found no side effects when injected into the endolymphatic sac or intratympanically. Another report found no harmful short‐term effects on audiological function in 21 patients with largely preserved hearing function …”